NanoForm Therapeutics is member of the DRGT Group. Headquartered in Dublin, Ireland, Druggability Technologies is developing and commercializing its proprietary NanoActive™ high throughput technology platform. This platform delivers improvements in compound solubility, permeability and pharmacokinetics that can be applied across a diverse universe of chemical and biological compounds.
One of its subsidiaries, NanoForm Therapeutics Ltd, based in the UK, focuses on selecting APIs with expected clinically meaningful benefits over original drug formulations, organizing and evaluating clinical assays of the NanoActive™ formula of the selected API, and supports DRGT’s effort to commercialize/license the clinically successful NanoActive APIs.
DRGT’s experience in improving the bioavailability and kinetic profile of drugs is born of a heritage of three decades of scientific and industrial knowledge gained through successful commercial ventures in bio- and chemo-informatics, combinatorial chemistry, chemical genomics, flow chemistry, colloidal chemistry, and nanotechnology.